StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of NASDAQ EVGN opened at $1.57 on Wednesday. The stock has a market capitalization of $8.43 million, a P/E ratio of -0.35 and a beta of 1.30. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40. The business’s 50 day moving average is $1.59 and its two-hundred day moving average is $2.62.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.